Evaluation of Tumor Control Probability and Normal Tissue Complication Probability of Breast Cancer Treatment Plan in Post Mastectomy Radiation Therapy

S. Herwiningsih, F. Yuana, R. Latifah, A. Hidayat, D. P. Rahmahtullah, I. Alviani, F. K. Hentihu

Abstract


Radiotherapy has been widely used to treat cancer, including breast cancer treatment, which can be given after patients undergo mastectomy procedures. This study aims to evaluate tumor control probability (TCP) and normal tissue complication probability (NTCP) of three-dimensional conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) treatment planning in post-mastectomy breast cancer radiation therapy. Twenty clinical breast cancer treatment plans delivered using 3DCRT were evaluated retrospectively. The IMRT plans were created for the same patients. The dose-volume histograms of each plan were extracted from the Treatment Planning System (TPS) computer which were then used to compute the TCP and NTCP for each plan. The TCP was calculated using the Poisson model and the NTCP was calculated using the Lyman-Kutcher-Burman (LKB) model. The NTCP was calculated for normal lung tissue, heart, esophagus, and spinal cord. The results show that the TCP of the 3DCRT and IMRT plans are not significantly different, with a value of above 99 %. The NTCP of the left lung is lower in the IMRT plans while the NTCP of the esophagus is lower in the 3DCRT plans. The NTCP for the heart, spinal cord, and right normal lung are zero in all plans.

Keywords


Breast cancer; Normal tissue complication probability; post mastectomy; Radiation Therapy; Tumor Control Probability

Full Text:

PDF

References


H. Sung, J. Ferlay, R.L. Siegel et al., CA Cancer J. Clin. 71 (2021) 209.

X. Yang, C. Zhu and Y. Gu, PLoS One 10 (2015) e0125655.

A. Burguin, C. Diorio and F. Durocher, J. Pers. Med. 11 (2021) 808.

T. A. Moo, R. Sanford, C. Dang et al., PET Clin. 13 (2018) 339.

I. Ratosa, G. Plavc, N. Pislar et al., Cancers 13 (2021) 4044.

C. Hennequin, Y. Belkacémi, C. Bourgier et al., Cancer/Radiothérapie 26 (2022) 221.

B. Warkentin, P. Stavrev, N. Stavreva et al., J. Appl. Clin. Med. Phys. 5 (2004) 50.

Yim, C. Suttie, R. Bromley et al., J. Med. Radiat. Sci. 62 (2015) 184.

S. Herwiningsih, A. Naba, S. Rianto et al., Indonesian Physical Review 6 (2023) 284.

D. N. Teguh, R. B. Raap, H. Struikmans et al., Radiat. Oncol. 11 (2016) 130.

A. Shanei, A. Amouheidari, I. Abedi et al., Int. J. Radiat. Res. 18 (2020) 315.

S. M. Bentzen, L. S. Constine, J. O. Deasy et al., Int. J. Radiat. Oncol. Biol. Phys. 76 (2010) S3.

L. B. Marks, S. M. Bentzen, J. O. Deasy et al., Int. J. Radiat. Oncol. Biol. Phys. 76 (2010) S70.

G. Gagliardi, L. S. Constine, V. Moiseenko et al., Int. J. Radiat. Oncol. Biol. Phys. 76 (2010) S77.

X. Wei, H. H. Liu, S. L. Tucker et al., Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 707.

M. Werner-Wasik, E. Yorke, J. Deasy et al., Int. J. Radiat. Oncol. Biol. Phys. 76 (2010) S86.

J. P. Kirkpatrick, A. J. Van Der Kogel, and T. E. Schultheiss, Int. J. Radiat. Oncol. Biol. Phys. 76 (2010) S42.

Uzan and A. E. Nahum, Br. J. Radiol. 85 (2012) 1279.

Herwiningsih, Dosimetric Verification of Stereotactic Body Radiotherapy Treatment Plans for Early Stage Non-Small Cell Lung Cancer Using Monte Carlo Simulation, Ph.D. Thesis, Queensland University of Technology (2017).

K. S. T. Abi, S. Habibian, M. Salimi et al., Arch. Breast Cancer 8 (2021) 192.

X. S. Qi, J. White, X. A. Li, Radiother. Oncol. 100 (2011) 282.

J. H. Chang, C. Gehrke, R. Prabhakar et al., Physica Med. 32 (2016) 248.

F. K. Hentihu, A. K. Anto and R. S. Nugroho, Atom Indones. 48 (2022) 9.

S. Adeneye, M. Akpochafor, B. Adegboyega et al., Eur. J. Breast Health 17 (2021) 247.

J. Wang, X. Li, Q. Deng et al., Med. Dosim. 40 (2015) 190.

H. Liu, X. Chen, Z. He et al., Comput. Med. Imaging Graphics 54 (2016) 1.

S. Bi, R. Zhu and Z. Dai, Radiat. Oncol. 17 (2022) 60.




DOI: https://doi.org/10.55981/aij.2024.1423



Copyright (c) 2024 Atom Indonesia

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.